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Eleven new 12-amino-6,7,10,11-tetrahydro-7,11-methanocycloocta[b]quinoline derivatives [tacrine
(THA)-huperzine A hybrids, rac-21-31] have been synthesized as racemic mixtures and tested
as acetylcholinesterase (AChE) inhibitors. For derivatives unsubstituted at the benzene ring,
the highest activity was obtained for the 9-ethyl derivative rac-20, previously prepared by our
group. More bulky substituents at position 9 led to less active compounds, although some of
them [9-isopropyl (rac-22), 9-allyl (rac-23), and 9-phenyl (rac-26)] show activities similar to
that of THA. Substitution at position 1 or 3 with methyl or fluorine atoms always led to more
active compounds. Among them, the highest activity was observed for the 3-fluoro-9-methyl
derivative rac-28 [about 15-fold more active than THA and about 9-fold more active than (-)-
huperzine A]. The activity of some THA-huperzine A hybrids (rac-19, rac-20, rac-28, and rac-
30), which were separated into their enantiomers by chiral medium-pressure liquid chroma-
tography (chiral MPLC), using microcrystalline cellulose triacetate as the chiral stationary
phase, showed the eutomer to be always the levorotatory enantiomer, their activity being
roughly double that of the corresponding racemic mixture, the distomer being much less active.
Also, the activity of some of these compounds inhibiting butyrylcholinesterase (BChE) was
tested. Most of them [rac-27-31, (-)-28, and (-)-30], which are more active than (-)-huperzine
A as AChE inhibitors, turned out to be quite selective for AChE, although not so selective as
(-)-huperzine A. Most of the tested compounds 19-31 proved to be much more active than
THA in reversing the neuromuscular blockade induced by d-tubocurarine. Molecular modeling
of the interaction of these compounds with AChE from Torpedo californica showed them to
interact as truly THA-huperzine A hybrids: the 4-aminoquinoline subunit of (-)-19 occupies
the same position of the corresponding subunit in THA, while its bicyclo[3.3.1]nonadiene
substructure roughly occupies the same position of the corresponding substructure in (-)-
huperzine A, in agreement with the absolute configurations of (-)-19 and (-)-huperzine A.
Introduction
It is well-known that many neurotransmitter systems
are implicated in the etiology of Alzheimer’s disease
(AD), a cholinergic deficit having being clearly estab-
lished.1-5 Accordingly, enhancement of the central cho-
linergic function has been regarded as one of the most
promising approaches for treating AD patients, mainly
by means of acetylcholinesterase (AChE) inhibitors6,7
such as the recently marketed tacrine (THA, Cognex,
1),8 donepezil (Aricept, 2),9 or rivastigmine (Exelon, 3)10
(Figure 1).
Much work has been done in the past few years for
the development of more potent, selective, and safe
AChE inhibitors.11 Among them, huperzine A, an alka-
loid isolated from Huperzia serrata, has been proposed
as a potent drug for treating AD. Some huperzine A
derivatives (5 and 6) more potent than the natural
product were also developed by modeling the interaction
of huperzine A12 (7) with AChE.13 Some time ago, we
carried out the synthesis and evaluation of several THA-
related AChE inhibitors such as 4,14 formally derived
from THA by molecular duplication. Moreover, some
new THA-based compounds, containing two THA sub-
units with their amino groups connected by an oligo-
methylene chain, such as 8, were designed taking into
account the existence of two binding sites for THA in
AChE.15 Recently, we have published the synthesis and
pharmacological evaluation of several derivatives, de-
signed by combination of the pharmacophores of hu-
perzine A (carbobicyclic substructure) and THA (4-
aminoquinoline substructure).16 Although compound 9,
which incorporated the carbobicyclic substructure of
huperzine A and the 4-aminoquinoline substructure of
THA, was less active than THA, the derivatives rac-19
and rac-20 (Scheme 1), lacking the ethylidene substitu-
ent at the methylene bridge, were 2-4-fold more active
than THA. It is worth noting that the introduction of
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substituents such as alkyl, alkoxy, or oxo at the meth-
ylene bridge as well as the substitution of this bridge
by an o-phenylene one or the substitution of the benzene
ring of the 4-aminoquinoline moiety by a cyclopentene
ring resulted in much less active compounds. These
results led us to prepare new derivatives of 19 and 20,
bearing different alkyl groups at position 9 or substi-
tuted on the 4-aminoquinoline moiety, and to evaluate
the pharmacological activity of both enantiomers of
some of these compounds.17 In addition, the modeling
of the interaction of these hybrid compounds with the
AChE of Torpedo californica18 was also studied, taking
advantage of the previous work carried out with THA19
and (-)-huperzine A.20
Chemistry
The synthesis of compounds rac-21-31 was carried
out by Friedla¨nder condensation of the corresponding
enone rac-13 and o-aminobenzonitrile 14-18 (Scheme
1).
Most of the required starting enones have been
previously described: rac-13a,21-23 rac-13b,d,g,i,23 and
rac-13c.17 Enones rac-13e,f were prepared following a
procedure previously developed by our group, based on
the silica gel-promoted fragmentation of the mesylates
12 derived from the corresponding 3-alkyl-2-oxa-1-
adamantanols 11.23 Oxaadamantanols 11, conveniently
substituted at position 3, were obtained by reaction of
diketone 10 with the required organolithium or orga-
nomagnesium reagents. For a given oxaadamantanol,
yields were better using the organolithium reagent.23
In this way, using vinyllithium and allyllithium, ox-
aadamantanols 11c,f were obtained in 59% and 57%
yield, respectively. Reaction of 10 with isopropyllithium
did not afford the desired oxaadamantanol 11e, no
defined product being isolated from this reaction. Also,
treatment of 10 with tert-butyllithium did not afford the
expected oxaadamantanol 11h, 3-(3,3-dimethylbutyl)-
2-oxa-1-adamantanol (11j) being isolated instead, in
45% yield. The formation of 11j can be rationalized by
reaction of 10 with 3,3-dimethylbutyllithium. This or-
ganolithium reagent can be formed by reaction of tert-
butyllithium with ethylene,24 formed by cleavage of the
THF on reaction with tert-butyllithium.25 These nega-
tive results can be explained taking into account that
some carbonyl compounds, such as diketone 10, are
susceptible to undergo some so-called abnormal reac-
tions (enolization, reduction, aldol condensation, or
pinacol coupling) on attempted addition of simple or-
ganolithium or Grignard reagents. Organocerium re-
agents have been found to be extremely useful in these
cases since these abnormal reactions are remarkably
Figure 1. Structures of some known AChE inhibitors.
Scheme 1. Synthetic Procedure for the Preparation of Hybrids rac-19-31
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suppressed.26 Thus, organocerium reagents react readily
with ketones at low temperature to give the addition
products in good to high yields. In fact, reaction of
diketone 10 with i-PrCeCl2, prepared by treatment of
i-PrLi with anhydrous CeCl3,27 afforded oxaadaman-
tanol 11e in 58% yield. Similarly, reaction of 10 with
t-BuCeCl2 gave 11h in 54% yield. Although oxaada-
mantanols 11a,b had been already prepared by reaction
of diketone 10 with the corresponding organolithium
compound (84% and 76% yield, respectively), we syn-
thesized them more efficiently by using the correspond-
ing organocerium reagent. Thus, treatment of commer-
cial MeMgBr or EtMgBr with anhydrous CeCl3, followed
by addition of diketone 10, led to oxaadamantanol 11a
or 11b in higher yields (91% and 85%, respectively) than
those previously obtained with the corresponding orga-
nolithium reagents.
Mesylates 12c,e,f,h were prepared in high yields by
reaction of the corresponding oxaadamantanols with
methanesulfonyl chloride following a standard proce-
dure.28 Reaction of mesylates 12e,f with silica gel in
CH2Cl2 at room temperature for 3-4 h afforded the
expected enones rac-13e,f in 43% and 50% yield, re-
spectively, after column chromatography. In both cases,
oxaadamantanols (11e,f) were also obtained as byprod-
ucts in 11% and 21% yield, respectively. The fragmenta-
tion of mesylate 12h was even easier. In this case, a
simple heating of a suspension of 12h in hexane under
reflux for 30 min afforded the expected enone rac-13h
in 80% yield. However, enone 13c could not be obtained
from mesylate 12c neither by reaction with silica gel
nor with concentrated H2SO4 in methanol, complex
mixtures of products being obtained instead.
Reaction of enones rac-13d,g,i, previously prepared
in our group,23 and of the new ones rac-13e,f,h with
2-aminobenzonitrile (14) catalyzed by AlCl3 in 1,2-
dichloroethane under reflux gave rise in moderate to
excellent yields to the corresponding racemic amino-
quinolines rac-21-26. These compounds were trans-
formed into the corresponding hydrochlorides and crys-
tallized from the appropriate solvent (see Experimental
Section). Worthy of note, as previously observed,16 only
the shown aminoquinolines, having the heterocyclic ring
and the endocyclic C-C double bond in an anti-arrange-
ment, were observed. This fact may be explained taking
into account the mechanism of this reaction, which is
illustrated in Scheme 2 for the reaction of enone 13a
and o-aminobenzonitrile (14). Reaction of 13a and 14
would give imine 32 which would be in equilibrium with
two regioisomeric enamines (33 and 34), the anti-
enamine 33 being reasonably the thermodynamically
more stable, as is the case for the anti-enamine 37,
obtained by reaction of ketone 36 with pyrrolidine
(Scheme 3).29 Similarly, aminoquinoline 19 is expected
to be more stable than 35, and this greater stability
must also be reflected in the transition states leading
from enamines 33 and 34 to aminoquinolines 19 and
35. If the above hypothesis is correct, kinetically con-
trolled Friedla¨nder cyclization of the anti-enamine 33
would give preferentially the anti-aminoquinoline 19,
the only observed regioisomer. In no case were the syn-
aminoquinolines corresponding to 19-26 observed.
The best AChE inhibitory activities of compounds rac-
19-26 were observed for the methyl and ethyl deriva-
tives rac-19 and rac-20 (see Pharmacology). These
results prompted us to carry out the synthesis and
evaluation of derivatives of 19 and 20, bearing one alkyl
or halogen substituent at different positions on the
benzene ring. Thus, reaction of enones rac-13a,b with
2-amino-4-methylbenzonitrile (15) catalyzed by AlCl3 in
1,2-dichloroethane under reflux afforded the corre-
sponding racemic aminoquinolines rac-27 and rac-30,
in 91% and 25% yield, respectively.
However, the Friedla¨nder condensation of rac-13b
with 2-amino-6-methylbenzonitrile (16) in 1,2-dichloro-
ethane under reflux for 7 h did not give the expected
aminoquinoline rac-31, adamantanediamine 38 being
isolated instead in low yield. When this reaction was
carried out under more vigorous conditions (1,2-dibro-
moethane under reflux for 18 h), aminoquinoline rac-
31 was obtained in 65% yield. Steric hindrance during
the carbon-carbon bond-forming step of the Friedla¨nder
reaction due to the 6-methyl substituent of 16 may
explain the observed rate decrease for the formation of
rac-31.
The formation of compound 38 can be rationalized,
as shown in Scheme 4, under acid catalysis. Condensa-
tion of enone rac-13b with aminobenzonitrile 16 would
give an imine. Acid-catalyzed isomerization of the
endocyclic carbon-carbon double bond to an exocyclic
position followed by electrophilic addition of the proto-
nated imine would give a carbocation which, on reaction
with a second molecule of 16, would give 38. This
reaction sequence must not be much affected by the
presence of the methyl group of 16, and thus it can take
Scheme 2. Alternative Pathways in the Friedla¨nder
Reaction of Enones 13 and Aminobenzonitrile 14
Scheme 3. Main Enamine 37 Formed from Keto
Carbamate 36
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place under moderate reaction conditions, if an acid
catalyst is present.
The Friedla¨nder condensation of rac-13a with 2-amino-
4-fluorobenzonitrile (17) and 2-amino-6-fluorobenzoni-
trile (18) under standard conditions allowed us to obtain
the fluorinated derivatives rac-28 and rac-29 in 74% and
66% yield, respectively.
The excellent pharmacological results obtained with
rac-28 and rac-30 (see Pharmacology) led us to carry
out their chromatographic resolution by chiral MPLC
in a manner similar to that described for rac-19 and
rac-20.17 In this way we could obtain both enantiomers
of compounds 28 and 30 in an adequate scale for the
pharmacological tests. The (7R,11R)-configuration was
assigned to (+)-28 and (+)-30 and the (7S,11S)-config-
uration to (-)-28 and (-)-30, taking into account the
configuration of the (+)- and (-)-enantiomers of a closely
related derivative, which was determined by X-ray
diffraction analysis.17
All of the new compounds have been fully character-
ized through their spectroscopic and analytical data (IR,
1H and 13C NMR spectra, and elemental analysis). The
1H and 13C NMR spectra of all of these compounds were
fully assigned through the COSY 1H/1H and COSY 1H/
13C spectra. Differentiation among the pairs of protons
8(9)-Hendo/exo and 4(10)-Hendo/exo of mesylates 12
could be easily carried out taking into account the
presence in the COSY 1H/1H spectra of cross-peaks
corresponding to W-couplings between the exo protons
of these positions. The more deshielded proton of the
8(9)-Hendo/exo pair was assigned to the endo one. In
our previous work,23 the assignment of the pair of
protons 8(9)-Hendo/exo of some related mesylates car-
ried out by comparison with the corresponding alcohols
was interchanged, since no W-coupling between the exo
protons of these positions was observed. For the assign-
ment of the quaternary carbon atoms of compounds rac-
21-31, previous work14,16 was taken into account.
Pharmacology
To determine the potential interest of compounds 19-
31 for the treatment of AD, their AChE inhibitory
activity was assayed by the method of Ellman et al.30
on AChE from bovine erythrocytes. For the most active
compounds and to establish their selectivity, their
butyrylcholinesterase (BChE) inhibitory activity was
also assayed by the same method on human serum
BChE. Most of them were further analyzed in a periph-
eral cholinergic synapse, such as skeletal neuromuscu-
lar junction. In this analysis, the ability to reverse the
d-tubocurarine-induced neuromuscular blockade, a well-
known effect of AChE inhibitors,31 was tested.
Table 1 summarizes the data comparing AChE and
BChE inhibition as well as the ratio between BChE and
AChE activities and the reversion of the neuromuscular
blockade of the hybrid compounds and the reference
compounds THA and (-)-huperzine A. As this table
shows, (-)-huperzine A is about 2-fold more active than
tacrine, while hybrid compounds rac-20 and rac-27-
31 are clearly more active than (-)-huperzine A as
AChE inhibitors. It is worth noting that the enantio-
enriched compounds (-)-19, (-)-20, (-)-28, and (-)-30
are about 2-fold more active than their racemic mix-
tures, while their enantiomers are by far less potent.
The rest of the compounds (rac-21-26) are slightly less
potent than (-)-huperzine A.
About the BChE activity, it is worth noting that THA
is 3-fold more active toward BChE than toward AChE,
while (-)-huperzine A is highly selective for AChE.
Among the hybrid compounds, the more active deriva-
tives [rac-27-31, (-)-28, and (-)-30] are quite selective
inhibiting AChE. Most of these compounds are also
Scheme 4. Possible Mechanistic Pathway for the
Formation of Adamantane Derivative 38 from Enone
rac-13b and Aminobenzonitrile 16
Table 1. Pharmacological Data of Tacrine, (-)-Huperzine A,
and Compounds 19-31âHCla
IC50 (nM)a
compd AChE BChE
BChE IC50/
AChE IC50
AI50
(nM)
tacrine 130 ( 10 43.9 ( 1.7 0.34 71700
(-)-huperzine A 74 ( 5.5 >105 >103 b
rac-19 65 ( 15 126 ( 21 1.9 176
(+)-19 (87% ee) 329 ( 58 316 ( 12 0.96 c
(-)-19 (90% ee) 47.1 ( 6.3 89.0 ( 0.2 1.9 613
rac-20 38.5 ( 4 79.3 ( 9.7 2.1 84
(+)-20 (99% ee) 888 ( 141 109 ( 7 0.12 d
(-)-20 (99% ee) 27.4 ( 3.1 63.3 ( 8.6 2.3 336
rac-21 431 ( 94 b 260
rac-22 103 ( 17 b b
rac-23 150 ( 16 b d
rac-24 280 ( 87 b d
rac-25 267 ( 87 b b
rac-26 126 ( 8 b d
rac-27 12.4 ( 2.3 449 ( 40 36 b
rac-28 8.5 ( 1.8 197 ( 30 23 8.0
(+)-28 (99% ee) 1480 ( 180 2930 ( 20 2 b
(-)-28 (99% ee) 3.49 ( 0.84 138 ( 20 40 48.6
rac-29 31.4 ( 0.8 543 ( 89 17 73.5
rac-30 12.0 ( 2.2 208 ( 27 17 b
(+)-30 (96% ee) 485 ( 57 115 ( 17 0.24 d
(-)-30 (97% ee) 4.5 ( 0.8 347 ( 39 77 213
rac-31 29.8 ( 6.2 512 ( 90 17 566
a Values are expressed as mean ( standard error of the mean
of at least four experiments. IC50, 50% inhibitory concentration of
acetylcholinesterase (from bovine erythrocytes) or butyrylcho-
linesterase (from human serum) activity; AI50, drug concentration
that reaches 50% of antagonism index (AI). All compounds were
used in the form of hydrochlorides, and the values were determined
taking into account the water of crystallization deduced from the
elemental analysis. b Not determined. c Only 22.8% reversion was
obtained at 10 íM. d No reversion at 10 íM concentration.
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clearly more potent than THA in reversing the neuro-
muscular blockade, while others show lower or no
activity when used at a concentration of 10 íM.
Discussion
Recently we reported that rac-19 and rac-20 were
about 2- and 4-fold more active than THA as AChE
inhibitors. An examination of the results in Table 1
shows that the substitution of the methyl or ethyl group
at position 9 (R1 substituent), present in 19 and 20, by
different alkyl (propyl, isopropyl, butyl, tert-butyl),
phenyl, or allyl substituents leads to compounds which
are equipotent to or somewhat less active than THA.
Thus, the 9-isopropyl-, 9-allyl-, and 9-phenyl-substituted
aminoquinolines rac-22, rac-23, and rac-26, respectively,
exhibited approximately the same AChE inhibitory
activity than THA, while the introduction of a propyl
(rac-21), butyl (rac-24), or tert-butyl (rac-25) group at
position 9 results in an activity 2-3-fold lower.
On the other hand, the introduction of a methyl or
fluorine substituent at positions 1 or 3 (R2 and R3
substituents) results in an enhanced AChE inhibitory
activity, especially when this substituent is located at
position 3. Thus, the 3-methyl derivatives rac-27 and
rac-30 and the 3-fluoro derivative rac-28 are 6-, 6-, and
9-fold more potent than (-)-huperzine A, respectively,
while the 1-methyl and 1-fluoro derivatives rac-31 and
rac-29 are approximately 2.5-fold more potent than (-)-
huperzine A. The increase in the AChE activity of the
1- or 3-substituted derivatives rac-27-31 parallels the
results reported by Kawakami et al.32 for other THA
derivatives.
We have evaluated both enantiomers of some of these
compounds (19, 20, 28, and 30). Always the (-)-
enantiomer is the more active one (eutomer). Taking
into account their enantiomeric excesses (ee’s), their
activity is roughly 2-fold that of the corresponding
racemic mixtures. Moreover, the (+)-enantiomers (dis-
tomers) are much less active than the corresponding
racemic mixtures, especially if their activity is corrected
for the presence of the (-)-enantiomer by assuming
additive effects.
In connection with the AChE inhibitory activity of
compounds 19-31, some qualitative structure-activity
relationships can be derived from the above data: (a)
the optimal activity is found when there is a methyl or
ethyl group at position 9 (bicyclo[3.3.1]nonadiene sub-
structure); (b) the introduction of a methyl group or a
fluorine atom at position 1 or 3 (aminoquinoline sub-
structure) results in a highly enhanced activity, the
3-substituted derivatives being the more active com-
pounds; (c) the levorotatory enantiomer of each racemic
mixture is the more potent one.
Although it has not been completely clarified if the
selectivity in inhibiting AChE versus BChE results in
low peripheral cholinergic effects in AD patients,33 we
determined the BChE inhibitory activity of the more
active compounds toward AChE (Table 1). Most of the
compounds tested were very selective for AChE, espe-
cially rac-27-31 (by factors between 17 and 36) and the
levorotatory enantiomers of some of them [(-)-28 and
(-)-30, by factors of 40 and 77, respectively, the last one
being the most selective]. Other compounds showed
selectivity for the BChE such as (+)-20 and (+)-30.
Finally, (+)-19 did not distinguish between both en-
zymes. Worthy of note, (-)-huperzine A is highly selec-
tive for AChE (see Table 1).
For the reversion of the neuromuscular blockade, the
more active compounds are the fluorinated derivatives
rac-28, (-)-28, and rac-29 and also rac-20 (8960-, 1475-,
975-, and 855-fold more potent than THA, respectively).
Other compounds that are more potent than THA as
AChE inhibitors, such as (-)-19, (-)-20, (-)-30, and rac-
31, are also more active in this assay (120-340-fold
more potent than THA). Compound rac-21 exhibit
greater activity than THA in this assay (275-fold)
despite its lower AChE inhibitory activity. The discrep-
ancy observed on the potency of racemates and enan-
tiomers to inhibit AChE and to reverse neuromuscular
blockade deserves further comment. The biochemical
studies used (i.e., determination of AChE inhibition) test
the ability of a compound to inhibit enzyme activity;
therefore, they only analyze the drug effects in a single
mechanism. The pharmacological testing (i.e., determi-
nation of neuromuscular blockade reversion) analyzes
the magnitude of an effect regardless of the implicated
mechanisms. The pharmacological testing adds valuable
information over the biochemical studies, as it evaluates
how the drug enhances the activity of a cholinergic
synapse and not merely the action on an isolated
enzyme. However, drugs may act in several targets
(enzymes, receptors) at skeletal neuromuscular junc-
tions,34 and indeed, some actions, such as blockade of
nerve potassium chanels or activation of presynaptic M1
receptors, may facilitate neurotransmission at this
level.35 Thus, THA may enhance acetylcholine release
besides its AChE inhibitory action.36 We did not test
each of these possibilities to explain the discrepancies
between the effects of racemates and enantiomers.
However, some preliminary and unpublished data have
shown that some of the present compounds bind to M1
receptors. Further work is in progress to gain more
knowledge about these unexpected actions.
Molecular Modeling. To understand the recognition
of 19 and to enable rational design of new derivatives,
we examined different binding modes of 19 in AChE.
Since 19 was conceived as a hybrid between THA and
huperzine A, our working hypothesis was to assume
that its binding to AChE shares some or all of the
features that modulate the binding of THA and hu-
perzine A. Accordingly, modeling of the interaction of
19 with the enzyme was based on the crystallographic
structures of the AChE complexes with THA19 and (-)-
huperzine A.20 To examine the suitability of the com-
putational approach (see Molecular Modeling: Meth-
ods), calculations were extended to the binding of THA
and the two enantiomers of huperzine A.
The energy-minimized structures of AChE complexed
with THA and (-)-huperzine A reproduce the basic
interactions between inhibitor and enzyme found in the
crystallographic structures.19,20 In the former complex
(Figure 2, left), THA is stacked between Trp84 and
Phe330 (the distance from THA to both indole and
benzene rings varies from 3.5 to 3.9 Å). The +NH group
is hydrogen-bonded to the carbonyl oxygen of His440
(2.9 Å), and the exocyclic amino group is well-hydrated,
three water molecules being less than 3.3 Å from the
nitrogen atom. These water molecules play a relevant
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structural role, since they connect the NH2 group to
Ser122 and Asp72. In the AChE-(-)-huperzine A
complex (Figure 2, right), the amido NH group is
hydrogen-bonded to a water molecule (2.9 Å), which in
turn interacts with Glu199, and to the main chain NH
group of Gly117. The protonated amino group is sur-
rounded by two water molecules lying approximately
at 3.0 Å, which are hydrogen-bonded to other residues,
like Asp72, Ser81, and Ser 122, or to other water
molecules. Likewise, this ammonium group is around
4.8 Å from the five-membered ring of Trp84 and the
benzene ring of Phe330. Finally, the carbonyl oxygen
of His440 is close (around 3.1 Å) to the ethylidene
methyl group, and the methyl group of the alicyclic
bridge is about 4.3 Å from Phe290.
The results in Table 2 indicate that (-)-huperzine A
binds better than THA.37 Owing to the approximations
underlying the computational model and to the fact that
the inhibitory potency was determined from pharma-
cological assays performed in biological systems other
than the T. californica enzyme, comparison with ex-
perimental data should be performed with caution.
Nevertheless, the results in Table 2 show qualitative
agreement with the experimental inhibitory data, which
indicate that (-)-huperzine A (IC50 47 nM inhibiting
AChE from rat hippocampal crude homogenates38 and
IC50 74 ( 5.5 nM inhibiting AChE from bovine eryth-
rocytes obtained in this work) is somewhat more active
than THA (IC50 59 nM inhibiting AChE from rat brain39
and IC50 130 ( 10 nM inhibiting AChE from bovine
erythrocytes obtained in this work).
To further analyze the reliability of calculations, we
examined the interaction of (+)-huperzine A with AChE.
The structure of (+)-huperzine A was oriented super-
imposing the pyridone ring with that of (-)-huperzine
A in the crystallographic complex to keep all of the basic
interactions of the NH, CO, and NH3+ groups. These
interactions are retained in the energy-minimized struc-
ture, and the most notable difference with regard to the
AChE-(-)-huperzine A complex is that the distance
from the NH3+ group to Trp84 increases by ca. 1.4 Å.
The results (Table 2) agree with the experimental fact
that (+)-huperzine A inhibits the enzyme near 40-fold
less potently than (-)-huperzine A.40,41 The smaller
binding of the (+)-enantiomer likely stems from the
weakening of the interaction between the NH3+ group
and Trp84, which supports the role of cation-ð interac-
tions in the binding of huperzine A,13,20,42,43 in agree-
ment with recent theoretical studies.44,45
Different binding modes that mimic the basic features
of the interaction of either THA or (-)-huperzine A were
examined for (-)-19 (Figure 3). In mode 1, the quinoline
rings of (-)-19 and THA are matched, and the bicyclo-
[3.3.1]nonadiene substructure of (-)-19 is over the
alicyclic ring of THA. In mode 2, (-)-19 has been rotated
180° along the largest molecular axis, so that the +NH
and NH2 groups are interchanged with regard to mode
1. Likewise, the molecule can be placed by rotating
around the axis passing through the nitrogen atoms,
Figure 2. Plot of the main interactions between the protein and the ligand [left, tacrine; right, (-)-huperzine A]. Residues Trp84
and Phe330, which lie above and below the ligand in the picture, are not shown for the sake of clarity.
Table 2. Contributions (kcal/mol) of the Electrostatic,
Lennard-Jones, and Solvent-Accessible Surface Terms to the
Binding Free Energy Determined for THA and Enantiomers of
Huperzine A
compd ¢Gelea ¢EL-J ¢GSAS
tacrine -5.0 ( 2.1 -39.1 -4.0
(-)-huperzine A -10.1 ( 2.1 -43.8 -4.3
(+)-huperzine A -7.7 ( 1.6 -40.1 -4.5
a Average value of seven separate Poisson-Boltzmann calcula-
tions (see Molecular Modeling: Methods). The standard deviation
is also given.
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so that the bicyclo[3.3.1]nonadiene substructure is over
the aromatic ring of THA (modes 3 and 4). With regard
to the huperzine A-like binding motifs, (-)-19 was
oriented to mimic the water-mediated contact between
the pyridone NH group of (-)-huperzine A and Glu199.
This was accomplished connecting either the +NH (mode
5) or NH2 (mode 6) groups. In the two cases the bicyclo-
[3.3.1]nonadiene substructure of (-)-19 occupies the
position of the corresponding substructure of (-)-hu-
perzine A. Rotation of (-)-19 around the axis passing
through the nitrogen atoms, as was performed in the
tacrine-like binding modes, was not considered, since
these orientations are sterically hindered owing to
unfavorable contacts with the AChE gorge. Finally, a
direct interaction between the +NH or NH2 groups and
Glu199 was also considered (modes 7 and 8). The same
binding modes were considered for the (+)-enantiomer
of 19. In the energy-minimized structures there were
no relevant changes in the position of the inhibitor with
regard to the starting orientation, and the interactions
were well-preserved. Likewise, the backbone in the
AChE gorge showed slight changes, and no remarkable
structural alterations were observed.
To discern the feasibility of the different binding
modes, the computed binding free energies were com-
pared in light of the inhibitory data, which indicate that
the (-)-enantiomer is more effective in inhibiting the
enzyme than the (+)-enantiomer (Table 1). Therefore,
the putative binding mode should be that leading to a
significant interaction energy and to a clear difference
in the binding for related compounds, particularly (+)-
and (-)-enantiomers. It is worth noting that comparison
of the results for the two enantiomers benefits from
cancellation of errors in the computed binding free
energies. The results in Table 3 allow us to exclude the
THA-like binding modes 2 and 4 and all of the huperzine
A-like binding modes, which in some cases (modes 5 and
7) lead to better interaction of the (+)-enantiomer. In
contrast, modes 1 and 3 provide the largest binding free
energy differences and clearly distinguish the binding
of the two enantiomers. Most of the interactions are
similar in modes 1 and 3 (see Figure 4). The hybrid
compound (-)-19 is stacked between Trp84 and Phe330
(the indole and benzene rings are about 3.5-3.9 Å from
the molecular plane). The +NH group is hydrogen-
bonded to the carbonyl oxygen of His440 (at around 2.9
Figure 3. Schematic views of the different tacrine-like (1-4) and (-)-huperzine A-like (5-8) binding modes considered for
compound (-)-19.
Table 3. Contributions (kcal/mol) of the Electrostatic,
Lennard-Jones, and Solvent-Accessible Surface Terms to the
Binding Free Energy Determined for Compounds (+)- and
(-)-19 in Their Protonated Formsa
mode ¢Gele ¢EL-J ¢GSAS ¢¢G
(-)-19
1b 0.0 0.0 0.0 0.0
2 4.4 2.2 -0.2 6.4
3 -1.4 0.3 0.1 -1.2
4 4.3 2.1 -0.1 6.3
5 3.6 1.0 -0.1 4.5
6 2.1 -0.1 -0.1 1.9
7 4.3 2.8 -0.1 7.0
8 2.6 1.2 0.0 3.8
(+)-19
1 1.6 4.8 -0.1 6.3
2 4.8 1.9 -0.1 6.6
3 0.0 4.1 0.0 4.1
4 3.0 4.5 -0.2 7.3
5 3.5 -0.4 0.1 3.2
6 3.6 1.8 -0.2 5.2
7 1.9 2.6 0.0 4.5
8 1.7 4.2 0.0 5.9
a Values are relative to the results determined for the binding
mode 1 of (-)-19. See Figure 3 for the schematic representation
of the different binding modes. b The absolute values (kcal/mol)
for the interaction of (-)-19 in mode 1 are -7.7 ( 1.6, -44.9, and
-4.5 for the electrostatic, Lennard-Jones, and solvent-accessible
surface contributions.
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Å). The exocyclic amino group is well-hydrated, and the
water molecules connect (-)-19 to the residues Asp72,
Ser81, Tyr121, and Ser122. Regarding the bicyclo[3.3.1]-
nonadiene substructure of (-)-19, the methyl group at
position 9 lies in a pocket formed by the residues
Phe290, Phe330, and Phe331 in mode 1, whereas it
occupies a region surrounded by Trp84, Trp432, and
Met83 in mode 3.
The suitability of modes 1 and 3 was further exam-
ined from calculations performed for the derivatives
9-ethyl [(-)-20], 9-propyl [(-)-21], and 9-methyl-3-fluoro
[(-)-28], whose inhibitory activity exhibits clear trends
compared to that of (-)-19 (see Table 1). These trends
are reflected in the results given in Table 4, since
extension from 9-ethyl to 9-propyl makes the binding
less favored, and the binding of the 9-methyl-3-fluoro
derivative is comparable or slightly better than that of
the 9-ethyl derivative. However, in mode 3 compounds
(-)-20 and (-)-28 interact worse than (-)-19 by nearly
3 kcal/mol, which disagrees with the measured change
in their inhibitory activity relative to the parent
9-methyl compound (see Table 1). On the contrary, the
binding of (-)-20 and (-)-28 is slightly better than that
of (-)-19 when mode 1 is considered, in agreement with
the experimental inhibitory data.
The preceding discussion suggests us to propose mode
1 as a putative binding model for the hybrid compounds.
As a final test, we performed a 500-ps molecular
dynamics simulation (see Molecular Modeling: Meth-
ods) of the AChE-(-)-19 complex with the inhibitor
oriented following binding mode 1. The structural
analysis showed that the complex remains stable along
all the simulations without suffering remarkable changes
in the interactions with the enzyme residues contribut-
ing to the binding. In addition, since human AChE
contains a Tyr residue instead of Phe330, we examined
the effect of this substitution on the binding of 19 by
replacing Phe330 by Tyr in the last structure collected
in the molecular dynamics simulation. The complex
between (-)-19 and the Phe330fTyr enzyme remained
stable during a subsequent 500-ps molecular dynamics
simulation. After energy minimization of the last struc-
ture collected in this latter simulation, the computed
binding free energy of (-)-19 was found to be 7.2 kcal/
mol better than that of the (+)-enantiomer, a value close
to that reported in Table 3 (6.3 kcal/mol) for the T.
californica enzyme. Therefore, the Phe330fTyr substi-
tution has no marked influence on the interactions
mentioned above for binding mode 1.
It is worth emphasizing that mode 1 mixes effectively
some of the binding features of THA and (-)-huperzine
A. Thus, the NH2 groups of THA and (-)-19 and the
Figure 4. Plot of the main interactions between the protein and (-)-19 for binding modes 1 (left) and 3 (right). Residues Trp84
and Phe330, which lie above and below the molecular plane of (-)-19 in the figure, are not shown for the sake of clarity.
Table 4. Contributions (kcal/mol) of the Electrostatic,
Lennard-Jones, and Solvent-Accessible Surface Terms to the
Binding Free Energy Determined for (-)-19 and Its 9-Ethyl
[(-)-20], 9-Propyl [(-)-21], and 9-Methyl-3-fluoro [(-)-28]
Derivatives in Their Protonated Forms, in Binding Modes 1
and 3a
compd ¢Gele ¢EL-J ¢GSAS ¢¢G
Mode 1
(-)-19 0.0 0.0 0.0 0.0
(-)-20 -0.1 -0.3 -0.3 -0.7
(-)-21 1.8 -0.4 -0.4 1.0
(-)-28 -0.4 -1.0 0.0 -1.4
Mode 3
(-)-19 0.0 0.0 0.0 0.0
(-)-20 3.9 -1.0 -0.1 2.8
(-)-21 5.2 -0.7 -0.4 4.1
(-)-28 3.3 -0.2 0.0 3.1
a Values are relative to the results determined for binding modes
1 and 3 of (-)-19 (see Table 3).
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NH3+ group of (-)-huperzine A occupy nearly the same
positions in the binding pocket (see Figure 5, left), which
allows to share a common set of interactions in this
region. Indeed, the quinoline ring of (-)-19 fits the
corresponding substructure in THA (Figure 5, left).
Therefore, attachment of substituents to the aromatic
ring in either (-)-19 or THA should have an analogous
effect on the inhibitory activity. This is confirmed by
the available experimental data, which indicate that
attachment of a fluorine atom at position 6 of THA
increases the activity by a factor of 2.5,32 and the same
substitution in rac-19 gives rac-28, which is 7.6-fold
more active than rac-19. The same effect is observed
when a chlorine atom is attached to the same position
in THA and 1,4-methylenetacrine46 and in dihydro-
quinazoline-based AChE inhibitors.47 On the other
hand, the bicyclo[3.3.1]nonadiene subunit of (-)-19 lies
in the same position occupied by the corresponding
fragment of (-)-huperzine A within the AChE binding
site (Figure 5, right), in accordance with their absolute
configurations.17 Again, the introduction of substituents
in this subunit should lead to parallel changes in the
inhibitory activity for the two compounds. To the best
of our knowledge, the inhibitory potency of (-)-hu-
perzine A derivatives with the methyl group at position
7 replaced by hydrogen, ethyl, propyl, or butyl groups
has not been reported yet. Nevertheless, replacement
of methyl by phenyl decreases the inhibitory activity by
at least 1000-fold.48 The same effect, although much less
pronounced, occurs in rac-19 upon substitution of the
9-methyl group by larger substituents such as propyl,
butyl, isopropyl, tert-butyl, and phenyl (Table 1). Finally,
let us note that these analogies concerning the effect of
substituents cannot be realized if one assumes that the
hybrid compound binds according to binding mode 3.
Even though the involvement of other binding sites
cannot be ruled out,49 the preceding considerations
suggest that mode 1 can be considered to be a putative
binding model to rationalize the AChE inhibitory activ-
ity of the hybrid derivatives. On the basis of the present
results, future studies directed at developing hybrid
compounds with improved inhibitory potency will be
valuable to gain better understanding on the structural
requirements involved in binding.
Conclusion
The AChE inhibitory activity of the THA-huperzine
A hybrids rac-19-31 herein described shows that, for
better activity, the substituent R1 at position 9 must be
ethyl or methyl. More bulky substituents and also the
absence of substituents at this position16 lead to less
active compounds. Substitution at position 1 (R2) or 3
(R3) with a methyl or fluorine atom always leads to
increased AChE inhibitory activity. For a given sub-
stituent, the activity is higher when the substituent is
located at position 3 (IC50 rac-31/IC50 rac-30 ) 2.5; IC50
rac-29/IC50 rac-28 ) 3.7). Also, for a given location of
the substituent, the activity is greater for the fluoro
derivative than for the methyl derivative (for example,
IC50 rac-27/IC50 rac-28 ) 1.5). The more active com-
pound prepared, rac-28, is about 9-fold more active than
(-)-huperzine A. Although the eutomer of compounds
19, 20, 28, and 30 is always the (-)-enantiomer, as in
the case of huperzine A, it is worth noting that their
absolute configurations17 are opposite to that of (-)-
huperzine A. The eutomers of these hybrid compounds
are roughly 2-fold more active than their racemic
mixtures, and thus, (-)-28 is about 21-fold more active
than (-)-huperzine A. Moreover, the more active AChE
inhibitors of this series proved to be quite selective in
Figure 5. Two views of the superimposition of the inhibitors tacrine (magenta), (-)-huperzine A (blue), and (-)-19 (green) in the
orientations corresponding to their energy-minimized structures of the inhibitor-AChE complexes.
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inhibiting AChE as compared with BChE. Thus, rac-
27-31 showed inhibitory activities toward AChE that
were 17-36-fold greater than those observed in inhibit-
ing BChE. A still greater selectivity was observed for
the eutomers of two of these compounds [(-)-28 and (-)-
30] which were respectively 40- and 77-fold more active
in inhibiting AChE than BChE. Most of the tested
compounds [for example, rac-19, (-)-19, rac-20, (-)-20,
rac-21, rac-28, (-)-28, rac-29, (-)-30, and rac-31] proved
to be also much more active than THA in reversing the
neuromuscular blockade.
Molecular modeling of these compounds with AChE
from T. californica provides a basis to suggest that they
interact as truly THA-huperzine A hybrids: the 4-ami-
noquinoline substructure of (-)-19 occupies the same
position of the corresponding subunit in THA, while the
bicyclo[3.3.1]nonadiene substructure of (-)-19 occupies
roughly the same position of the corresponding subunit
in (-)-huperzine A, a fact that is only possible for the
levorotatory eutomers of hybrids 19-31 and (-)-hu-
perzine A. Even though caution is needed because the
AChE from T. californica is somewhat different from
human AChE and because of the approximations of the
computational model, the results herein described pro-
vide a basis to pursue our efforts to develop compounds
with improved inhibitory activity.
Experimental Section
Chemistry. General Methods. Melting points were de-
termined in open capillary tubes with a MFB 595010M
Gallenkamp melting point apparatus. 1H NMR spectra were
recorded at 500 MHz on a Varian VXR 500 spectrometer, and
13C NMR spectra were recorded at 75.4 or 50.3 MHz on a
Varian Gemini 300 or 200 spectrometer. The chemical shifts
are reported in ppm (ä scale) relative to internal TMS, and
coupling constants are reported in hertz (Hz). COSY 1H/1H
experiments were performed using standard procedures, while
COSY 1H/13C were performed using the HMQC sequence with
an indirect detection probe. For the 13C and 1H NMR data of
oxaadamantanols 11 and mesylates 12, and of compounds rac-
21-31, see Tables 1, 3, 2, and 4, respectively, of Supporting
Information. For the NMR data of the rest of compounds,
enones rac-13 and compound 38, see the Experimental Section.
IR spectra were run on a FT/IR Perkin-Elmer model 1600
spectrophotometer. Absorption values are expressed as wave-
numbers (cm-1). Mass spectra were recorded on a Hewlett-
Packard HP-5988A spectrometer (electron impact). Optical
rotations were measured on a Perkin-Elmer model 241 pola-
rimeter. The specific rotation has not been corrected for the
presence of solvent of crystallization. Chiral HPLC analyses
were performed on a Waters model 600 liquid chromatograph
provided with a Waters model 486 variable ì detector, using
a CHIRALCEL OD-H column (25  0.46 cm) containing the
chiral stationary phase cellulose tris(3,5-dimethylphenylcar-
bamate). Conditions A: mixture of hexane/EtOH in the ratio
of 75:25 as eluent, flow 0.20 mL/min, ì ) 235 nm. Chiral
medium-pressure liquid chromatography (chiral MPLC) sepa-
ration was carried out on equipment which consisted of a pump
(Bu¨chi 688), a variable ì UV detector (Bu¨chi), and a column
(25  2.5 cm) containing microcrystalline cellulose triacetate
(15-25 ím) as the chiral stationary phase. Column chroma-
tography was performed on silica gel 60 AC.C. (70-200 mesh,
SDS, ref 2100027). For the TLC, aluminum-backed sheets with
silica gel 60 F254 (Merck, ref 1.05554) were used. CeCl3â7H2O
and t-BuLi were purchased from Fluka, while lithium, allyl
phenyl ether, vinyl bromide, methanesulfonyl chloride, and
AlCl3 were purchased from Aldrich. Anhydrous THF and Et2O
were distilled over sodium, and anhydrous CH2Cl2 was distilled
over P2O5. Analytical grade solvents were used for recrystal-
lizations, while pure synthesis solvents were used in extrac-
tions and column chromatography. Pure-for-synthesis 1,2-
dichloroethane and 1,2-dibromoethane were also used. Et3N
was distilled over KOH. Aminobenzonitriles 14 and 18 were
purchased from Fluka and ABCR, respectively, while 15-17
were prepared according to literature procedures.50-52 Elemen-
tal analyses were carried out at the Microanalysis Service of
the Centro de Investigacio´n y Desarrollo, C.I.D., Barcelona,
Spain, and are within (0.4% of the theoretical values.
3-Methyl-2-oxa-1-adamantanol (11a). CeCl3â7H2O (3.80
g, 10.2 mmol) was dried at 160 °C/1 Torr for 16 h and
suspended in anhydrous THF (50 mL). The suspension was
stirred at room temperature for 2 h, cooled to -78 °C, and
treated with a solution of MeMgBr (1 M solution in pentane,
8.10 mL, 8.10 mmol). The mixture was stirred at -78 °C for 1
h and treated dropwise with a solution of diketone 10 (0.50 g,
3.29 mmol) in anhydrous THF (10 mL). The reaction mixture
was stirred at -78 °C for 1 h, allowed to warm to room
temperature over 3 h, stirred at room temperature for 12 h,
and treated with saturated aqueous NH4Cl (20 mL). The
organic layer was separated, and the aqueous one was
extracted with CH2Cl2 (3  100 mL). The combined organic
layers were dried with Na2SO4 and evaporated under reduced
pressure. Sublimation of the resulting white solid residue (0.79
g) at 80 °C/0.5 Torr afforded pure oxaadamantanol 11a (0.50
g, 91% yield).
3-Ethyl-2-oxa-1-adamantanol (11b). This compound was
prepared from CeCl3â7H2O (3.80 g, 10.2 mmol), EtMgBr (1 M
solution in pentane, 8.10 mL, 8.10 mmol), and diketone 10
(0.50 g, 3.29 mmol) in a manner similar to that described for
11a. Sublimation of the resulting white solid residue (0.85 g)
at 80 °C/0.5 Torr afforded pure oxaadamantanol 11b (0.51 g,
85% yield).
3-Vinyl-2-oxa-1-adamantanol (11c). A cooled (-78 °C)
solution of vinyl bromide (0.50 mL, 758 mg, 7.09 mmol) in
anhydrous Et2O (16 mL) was treated dropwise over a 10-min
period with a solution of t-BuLi (1.5 M solution in pentane,
9.0 mL, 13.5 mmol) and stirred at -78 °C for 30 min. To the
resulting solution was added a solution of diketone 10 (0.50
g, 3.29 mmol) in anhydrous THF (15 mL) dropwise. The
reaction mixture was stirred at -78 °C for 30 min, allowed to
warm to 0 °C over 3 h, diluted with anhydrous THF (5 mL),
stirred at 0 °C for an additional 30-min period, quenched with
saturated aqueous NH4Cl (10 mL), and diluted with water (20
mL). The organic layer was separated, and the aqueous one
was extracted with CH2Cl2 (4  30 mL). The combined organic
layers were dried with Na2SO4 and evaporated under reduced
pressure to give a white solid residue (420 mg), which was
submitted to column chromatography [silica gel (21 g), hexane/
AcOEt mixtures]. On elution with hexane/AcOEt (85:15),
oxaadamantanol 11c (350 mg, 59% yield) was isolated: mp
84-87 °C after recrystallization from hexane; IR 3361 (OH).
Anal. (C11H16O2) C, H.
3-Isopropyl-2-oxa-1-adamantanol (11e). This compound
was prepared from CeCl3â7H2O (5.10 g, 13.7 mmol), i-PrLi
(0.12 M solution in pentane, 100 mL, 12.0 mmol),53 and
diketone 10 (1.00 g, 6.58 mmol) in a manner similar to that
described for 11a. Sublimation of the resulting white solid
residue (0.90 g) at 100 °C/1 Torr afforded pure oxaadamantanol
11e (0.75 g, 58% yield): mp 129-131 °C after recrystallization
from CH2Cl2; IR 3313 (OH). Anal. (C12H20O2) C, H.
3-Allyl-2-oxa-1-adamantanol (11f). A cooled (-15 °C)
suspension of lithium (9.94 g, 1.43 at.-g) in anhydrous THF
(250 mL) was treated dropwise over a 45-min period with a
solution of allyl phenyl ether (16.2 mL, 15.9 g, 118.3 mmol) in
anhydrous Et2O (60 mL).54 The cooling bath was removed, and
the mixture was stirred for 15 min, cooled again to -15 °C,
and treated dropwise over a period of 30 min with a solution
of diketone 10 (12.0 g, 78.9 mmol) in anhydrous THF (240 mL).
The reaction mixture was stirred at -15 °C for 30 min, and
then it was treated with saturated aqueous NH4Cl (200 mL).
The organic layer was separated, and the aqueous one was
extracted with CH2Cl2 (5  150 mL). The combined organic
extracts were washed with 1 N NaOH (4  100 mL), dried
with Na2SO4, and evaporated under reduced pressure. Subli-
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mation of the resulting solid residue (11.4 g) at 75 °C/3 Torr
afforded pure oxaadamantanol 11f (8.74 g, 57% yield): mp
100-101 °C; IR 3323 (OH). Anal. (C12H18O2) C, H.
3-tert-Butyl-2-oxa-1-adamantanol (11h). This compound
was prepared from CeCl3â7H2O (30.4 g, 81.6 mmol), t-BuLi (1.5
M solution in pentane, 54.0 mL, 81.0 mmol), and diketone 10
(4.00 g, 26.3 mmol) in a manner similar to that described for
11a. Sublimation of the resulting white solid residue (3.50 g)
at 80 °C/0.5 Torr afforded pure oxaadamantanol 11h (3.00 g,
54% yield): mp 125-127 °C after recrystallization from
hexane; IR 3323 (OH). Anal. (C13H22O2) C, H.
3-(3,3-Dimethylbutyl)-2-oxa-1-adamantanol (11j). To a
cooled (0 °C) solution of t-BuLi (1.5 M solution in pentane, 10
mL, 15.0 mmol) was added dropwise over a 30-min period a
solution of diketone 10 (1.00 g, 6.58 mmol) in anhydrous THF
(20 mL). The mixture was stirred at 0 °C for 30 min and
treated with saturated aqueous NH4Cl (30 mL). The organic
layer was separated, and the aqueous one was extracted with
Et2O (4  100 mL). The combined organic layers were dried
with Na2SO4 and evaporated under reduced pressure to give
a white solid residue (1.10 g), which was submitted to column
chromatography [silica gel (25 g), hexane/AcOEt mixtures]. On
elution with hexane/AcOEt (70:30), oxaadamantanol 11j (0.70
g, 45% yield) was isolated: mp 148-150 °C after sublimation
at 100 °C/1 Torr; IR 3314 (OH); EI-MS m/z 239 (M+ + 1, 3),
238 (M¥+, 19), 223 (M+ - CH3, 1), 221 (M+ - OH, 2), 206 (M¥+
- CH3 - OH, 2), 153 (M+ - C6H13, 72), 136 (M¥+ - C6H13 -
OH, 9). Anal. (C15H26O2) C, H.
General Procedure for the Preparation of Mesylates
12 from 2-Oxaadamantanols 11. A solution of the alcohol
11 (1 mmol) and anhydrous Et3N (1.4 mmol) in anhydrous CH2-
Cl2 (5 mL) was cooled to -10 °C. Methanesulfonyl chloride (1.6
mmol) was added dropwise over a period of 10 min, and the
reaction mixture was stirred at -10 °C for 30 min. The mixture
was poured into a mixture of 2 N HCl (5 mL) and crushed ice.
The organic layer was separated, and the aqueous one was
extracted with CH2Cl2 (4  20 mL). The combined organic
extracts were washed with saturated aqueous NaHCO3 (25
mL) and brine (25 mL), dried with Na2SO4, and evaporated
under reduced pressure to afford the corresponding mesylate
12.
3-Vinyl-2-oxa-1-adamantyl Methanesulfonate (12c).
This compound was prepared according to the procedure
described above: yield 0.26 g, 91%; IR 1357, 1166 (SO2). Anal.
(C12H18O4Sâ2/3H2O) C, H, S.
3-Isopropyl-2-oxa-1-adamantyl Methanesulfonate (12e).
This compound was prepared according to the procedure
described above: yield 0.36 g, 81%; IR 1350, 1184 (SO2). Anal.
(C13H22O4S) C, H, S.
3-Allyl-2-oxa-1-adamantyl Methanesulfonate (12f). This
compound was prepared according to the procedure described
above: yield 7.97 g, 98%; IR 1358, 1180 (SO2). Anal. (C13H20O4S)
C, H, S.
3-tert-Butyl-2-oxa-1-adamantyl Methanesulfonate (12h).
This compound was prepared according to the procedure
described above: yield 0.38 g, 89%; IR 1356, 1178 (SO2). Anal.
(C14H24O4S) C, H, S.
rac-7-Isopropylbicyclo[3.3.1]non-6-en-3-one (rac-13e).
A suspension of mesylate 12e (0.25 g, 0.91 mmol) and silica
gel (2 g) in CH2Cl2 (15 mL) was stirred at room temperature
for 4 h. After concentrating at reduced pressure, the resulting
solid residue was submitted to column chromatography through
silica gel (25 g) using mixtures of hexane/AcOEt as eluent. On
elution with hexane/AcOEt (75:25), enone rac-13e (70 mg, 43%
yield) was obtained, and on elution with hexane/AcOEt (60:
40), oxaadamantanol 11e (20 mg, 11% yield) was isolated. rac-
13e: mp 38-40 °C after sublimation at 60 °C/0.5 Torr; IR 1701
(CdO); 1H NMR (CDCl3) ä 0.92 (d, J ) 7.0 Hz, 3 H) and 0.93
(d, J ) 7.0 Hz, 3 H) [CH(CH3)2], 1.84 (br. d, J ) 17.5 Hz, 1 H,
8-Hendo), 1.93 (dm, J ) 12.5 Hz, 1 H) and 1.98 (dm, J  12.5
Hz, 1 H) (9-Hsyn and 9-Hanti), 2.08 [heptet, J ) 7.0 Hz, 1 H,
CH(CH3)2], 2.22 (dddd, J ) 15.5 Hz, J′ ) J′′ ) J′′′ ) 2.0 Hz, 1
H, 2-Hendo), 2.28 (dddd, J ) 14.5 Hz, J′  J′′  J′′′  2.5 Hz,
1 H, 4-Hendo), superimposes in part 2.32 (br. dd, J ) 17.5 Hz,
J′ ) 5.5 Hz, 1 H, 8-Hexo), 2.41 (dd, J ) 14.5 Hz, J′ ) 4.0 Hz, 1
H, 4-Hexo), 2.48 (dd, J ) 15.5 Hz, J′ ) 6.5 Hz, 1 H, 2-Hexo),
2.57 (m, 1 H, 1-H), 2.65 (m, 1 H, 5-H), 5.41 (dm, J ) 5.7 Hz,
1 H, 6-H); 13C NMR (CDCl3) ä 21.1 (CH3) and 21.5 (CH3) [CH-
(CH3)2], 30.0 (CH, C1), 30.5 (CH2, C9), 30.8 (CH, C5), 33.2
(CH2, C8), 34.6 [CH, CH(CH3)2], 46.7 (CH2, C4), 49.0 (CH2, C2),
122.0 (CH, C6), 142.4 (C, C7), 212.0 (C, C3). Anal. (C12H18O)
C, H.
rac-7-Allylbicyclo[3.3.1]non-6-en-3-one (rac-13f). A sus-
pension of mesylate 12f (7.50 g, 27.6 mmol) and silica gel (7.50
g) in CH2Cl2 (75 mL) was stirred at room temperature for 3 h
and concentrated at reduced pressure. The resulting solid
residue was submitted to column chromatography through
silica gel (100 g) using mixtures of hexane/AcOEt as eluent.
On elution with hexane/AcOEt (90:10), enone rac-13f (2.44 g,
50% yield) was isolated, and on elution with hexane/AcOEt
(80:20), oxaadamantanol 11f (1.13 g, 21% yield) was obtained.
rac-13f: bp 75 °C/1 Torr; IR 1697 (CdO); 1H NMR (CDCl3) ä
1.83 (br. d, J ) 18.0 Hz, 1 H, 8-Hendo), 1.94 (dm, J ) 13.0 Hz,
1 H, 9-Hanti), 1.99 (dddd, J ) 13.0 Hz, J′ ) 5.0 Hz, J′′ ) 2.5
Hz, J′′′ ) 1.0 Hz, 1 H, 9-Hsyn), 2.26 (dddd, J ) 15.5 Hz, J′ ) J′′
) J′′′ ) 2.0 Hz, 1 H, 2-Hendo), 2.32 (dddd, J ) 14.5 Hz, J′  J′′
 J′′′  2.0 Hz, 1 H, 4-Hendo), superimposes in part ca. 2.34
(br. dd, J ) 18.0 Hz, J′ ) 5.0 Hz, 1 H, 8-Hexo), 2.43 (dd, J )
14.5 Hz, J′ ) 4.5 Hz, 1 H, 4-Hexo), 2.50 (dddd, J ) 15.5 Hz, J′
) 6.5 Hz, J′′ ) J′′′ ) 1.0 Hz, 1 H, 2-Hexo), 2.58 (m, 1 H, 1-H),
2.62 (br. d, J ) 7.0 Hz, 2 H, CH2-CHdCH2), 2.69 (br. s, 1 H,
5-H), 4.99 (dm, J  17.5 Hz, 1 H, CH2-CHdCHtrans), 5.00 (dm,
J  10.0 Hz, 1 H, CH2-CHdCHcis), 5.48 (ddt, J ) 6.0 Hz, J′
) 2.3 Hz, J′′ ) 1.2 Hz, 1 H, 6-H), 5.70 (dm, J  18.0 Hz, 1 H,
CH2-CHdCH2); 13C NMR (CDCl3) ä 30.1 (CH, C1), 30.3 (CH2,
C9), 31.0 (CH, C5), 35.5 (CH2, C8), 41.5 (CH2, CH2-CHdCH2),
46.4 (CH2, C4), 49.0 (CH2, C2), 116.0 (CH2, CH2-CHdCH2),
125.3 (CH, C6), 135.0 (C, C7), 136.1 (CH, CH2-CHdCH2), 212.1
(C, C3). Anal. (C12H16O) C, H.
rac-7-tert-Butylbicyclo[3.3.1]non-6-en-3-one (rac-13h).
A stirred suspension of mesylate 12h (0.32 g, 1.11 mmol) in
hexane (50 mL) was heated under reflux for 30 min; to the
resulting mixture was added H2O (20 mL). The organic phase
was separated and washed successively with saturated aque-
ous NaHCO3 (50 mL) and brine (50 mL), dried with Na2SO4,
and evaporated under reduced pressure to afford the enone
rac-13h (0.17 g, 80% yield) as a white solid: mp 60-62 °C
after sublimation at 70 °C/1 Torr; IR 1699 (CdO); 1H NMR
(CDCl3) ä 0.95 [s, 9 H, C(CH3)3], 1.91 (dm, J ) 12.5 Hz, 1 H)
and 1.96 (dm, J  12.5 Hz, 1 H) (9-Hsyn and 9-Hanti), 1.97 (br.
d, J ) 17.5 Hz, 1 H, 8-Hendo), 2.21 (dddd, J ) 15.5 Hz, J′ ) J′′
) J′′′ ) 2.0 Hz, 1 H, 2-Hendo), 2.28 (dddd, J ) 14.5 Hz, J′  J′′
 J′′′  2.5 Hz, 1 H, 4-Hendo), 2.33 (ddm, J ) 17.5 Hz, J′ ) 6.0
Hz, 1 H, 8-Hexo), 2.41 (dd, J ) 14.5 Hz, J′ ) 4.2 Hz, 1 H, 4-Hexo),
2.47 (dddd, J ) 15.5 Hz, J′ ) 6.5 Hz, J′′ ) J′′′ ) 1.0 Hz, 1 H,
2-Hexo), 2.58 (m, 1 H, 1-H), 2.68 (m, 1 H, 5-H), 5.46 (dm, J )
5.7 Hz, 1 H, 6-H); 13C NMR (CDCl3) ä 28.9 [CH3, C(CH3)3],
30.1 (CH, C1), 30.2 (CH2, C9), 30.9 (CH, C5), 32.0 (CH2, C8),
35.1 [C, C(CH3)3], 46.8 (CH2, C4), 48.8 (CH2, C2), 121.1 (CH,
C6), 144.3 (C, C7), 211.9 (C, C3). Anal. (C13H20O) C, H.
General Procedure for the Preparation of Compounds
rac-21-31 from Enones rac-13 and 2-Aminobenzonitriles
14-18. To a suspension of anhydrous AlCl3 (2 mmol) and
2-aminobenzonitrile 14-18 (1.4 mmol) in 1,2-dichloroethane
(2 mL) was added a solution of enone rac-13 (1 mmol) in 1,2-
dichloroethane (12 mL) dropwise. The reaction mixture was
stirred under reflux for 7 h, allowed to cool to room temper-
ature, diluted with water (7 mL) and THF (7 mL), made basic
by addition of 5 N NaOH, and stirred at room temperature
for 30 min. The organic solvents were removed under reduced
pressure, and the residue was filtered. The solid residue was
submitted to column chromatography [silica gel (12 g), hexane/
AcOEt/MeOH mixtures] to give rac-21-31. A solution of rac-
21-31 in MeOH was treated with a solution of HCl (0.55 N
solution in Et2O, 3 equiv), and the solvent was evaporated to
give rac-21-31âHCl, which were recrystallized.
rac-12-Amino-6,7,10,11-tetrahydro-9-propyl-7,11-meth-
anocycloocta[b]quinoline Hydrochloride (rac-21âHCl).
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This compound was prepared according to the procedure
described above. On elution with AcOEt/MeOH (70:30), rac-
21 (2.82 g, 98% yield) was isolated. Subsequent treatment with
a solution of HCl (0.55 N solution in Et2O, 3 equiv), evapora-
tion, and recrystallization of the resulting solid from MeOH/
H2O (1:1) afforded pure rac-21âHCl (37% overall yield): mp
331-333 °C; IR 3500-2000 (max at 3320, 3146, 3071, 3029,
2943, 2900, 2871, 2820, 2686, 2371) (CH, NH, NH+), 1662 and
1586 (ar-C-C and ar-C-N). Anal. (C19H22N2âHCl) C, H, N, Cl.
rac-12-Amino-9-isopropyl-6,7,10,11-tetrahydro-7,11-
methanocycloocta[b]quinoline Hydrochloride (rac-
22âHCl). This compound was prepared according to the
procedure described above, with a reaction time of 12 h. On
elution with hexane/AcOEt (25:75), rac-22 (0.31 g, quantitative
yield) was isolated. Subsequent treatment with a solution of
HCl (0.55 N solution in Et2O, 3 equiv), evaporation, and
recrystallization of the resulting solid from MeOH/AcOEt (1:
4) afforded pure rac-22âHCl (48% overall yield): mp > 300 °C
dec; IR 3500-2500 (max at 3327, 3149, 2958, 2929, 2895, 2825,
2691) (CH, NH, NH+), 1656 and 1587 (ar-C-C and ar-C-N).
Anal. (C19H22N2âHCl) C, H, N, Cl.
rac-9-Allyl-12-amino-6,7,10,11-tetrahydro-7,11-metha-
nocycloocta[b]quinoline Hydrochloride (rac-23âHCl). This
compound was prepared according to the procedure described
above, but using 1 equiv of AlCl3 and 2 equiv of 2-aminoben-
zonitrile and a reaction time of 2.5 h. After the basic treatment,
the organic solvent was removed under reduced pressure, and
the aqueous residue was extracted with AcOEt (4  100 mL).
The combined organic extracts were dried with Na2SO4 and
evaporated to give an oily residue, which was submitted to
column chromatography. On elution with hexane/AcOEt (40:
60), rac-23 (0.38 g, 48% yield) was isolated. Subsequent
treatment with a solution of HCl (0.55 N solution in Et2O, 3
equiv), evaporation, and recrystallization of the resulting solid
from AcOEt/MeOH (3:2) afforded pure rac-23âHCl (31% overall
yield): mp > 300 °C dec; IR 3500-2000 (max at 3328, 3141,
3083, 3024, 2929, 2893, 2857, 2820, 2690, 2369) (CH, NH,
NH+), 1664 and 1585 (ar-C-C and ar-C-N). Anal. (C19H20N2â
HCl) C, H, N, Cl.
rac-12-Amino-9-butyl-6,7,10,11-tetrahydro-7,11-metha-
nocycloocta[b]quinoline Hydrochloride (rac-24âHCl). This
compound was prepared according to the procedure described
above. On elution with AcOEt/MeOH (70:30), rac-24 (2.40 g,
72% yield) was isolated. Subsequent treatment with a solution
of HCl (0.55 N solution in Et2O, 3 equiv), evaporation, and
recrystallization of the resulting solid from MeOH/H2O (2:3)
afforded pure rac-24âHCl (29% overall yield): mp 328-330 °C;
IR 3500-2000 (max at 3316, 3146, 3073, 3049, 2939, 2902,
2878, 2823, 2692, 2390) (CH, NH, NH+), 1660 and 1587 (ar-
C-C and ar-C-N). Anal. (C20H24N2âHCl) C, H, N, Cl.
rac-12-Amino-9-tert-butyl-6,7,10,11-tetrahydro-7,11-
methanocycloocta[b]quinoline Hydrochloride (rac-
25âHCl). This compound was prepared according to the
procedure described above, with a reaction time of 12 h. On
elution with hexane/AcOEt (30:70), rac-25 (2.70 g, 89% yield)
was isolated. Subsequent treatment with a solution of HCl
(0.55 N solution in Et2O, 3 equiv), evaporation, and recrystal-
lization of the resulting solid from MeOH/H2O (1:5) afforded
rac-25âHClâH2O (49% overall yield): mp > 300 °C dec; IR
3500-2500 (max at 3324, 3191, 3143, 2961, 2888, 2853, 2685)
(CH, NH, NH+), 1639 and 1587 (ar-C-C and ar-C-N). Anal.
(C20H24N2âHClâH2O) C, H, N, Cl.
rac-12-Amino-9-phenyl-6,7,10,11-tetrahydro-7,11-meth-
anocycloocta[b]quinoline Hydrochloride (rac-26âHCl).
This compound was prepared according to the procedure
described above. On elution with AcOEt/MeOH (90:10), rac-
26 (0.73 g, 50% yield) was isolated. Subsequent treatment with
a solution of HCl (0.55 N solution in Et2O, 3 equiv), evapora-
tion, and recrystallization of the resulting solid from AcOEt/
MeOH (1:1) afforded rac-26âHClâ5/4H2O (35% overall yield):
mp 206-207 °C; IR 3500-2500 (max at 3330, 3200, 3025,
2937, 2898, 2812, 2687) (CH, NH, NH+), 1647 and 1589
(ar-C-C and ar-C-N). Anal. (C22H20N2âHClâ5/4H2O) C, H, N,
Cl.
rac-12-Amino-6,7,10,11-tetrahydro-3,9-dimethyl-7,11-
methanocycloocta[b]quinoline Hydrochloride (rac-
27âHCl). This compound was prepared according to the
procedure described above, with a reaction time of 12 h. On
elution with hexane/AcOEt (20:80), rac-27 (3.20 g, 91% yield)
was isolated. Subsequent treatment with a solution of HCl
(0.55 N solution in Et2O, 3 equiv), evaporation, and recrystal-
lization of the resulting solid from MeOH/AcOEt (1:4) afforded
rac-27âHClâ5/3H2O (48% overall yield): mp 321-323 °C dec;
IR 3500-2500 (max at 3336, 3189, 2927, 2875, 2825, 2699)
(CH, NH, NH+), 1650 and 1592 (ar-C-C and ar-C-N). Anal.
(C18H20N2âHClâ5/3H2O) C, H, N, Cl.
rac-12-Amino-3-fluoro-6,7,10,11-tetrahydro-9-methyl-
7,11-methanocycloocta[b]quinoline Hydrochloride (rac-
28âHCl). This compound was prepared according to the
procedure described above, with a reaction time of 7 h. On
elution with hexane/AcOEt (30:70), rac-28 (2.27 g, 74% yield)
was isolated. Subsequent treatment with a solution of HCl
(0.55 N solution in Et2O, 3 equiv), evaporation, and recrystal-
lization of the resulting solid from MeOH/H2O (1:3) afforded
rac-28âHClâ2/3H2O (42% overall yield): mp 220-222 °C dec;
IR 3700-2400 (max at 3334, 3026, 3013, 2926, 2826, 2701)
(CH, NH, NH+), 1651 and 1591 (ar-C-C and ar-C-N). Anal.
(C17H17FN2âHClâ2/3H2O) C, H, N, Cl.
Preparative Resolution of rac-28 by Chiral MPLC:
(+)-(7R,11R)-28 and (-)-(7S,11S)-28. The chromatographic
resolution of rac-28 was carried out by using MPLC equipment
provided with a column (25  2.5 cm) containing microcrys-
talline cellulose triacetate (15-25 ím), pretreated with a 0.1%
solution of Et3N in EtOH, as the chiral stationary phase. The
sample of rac-28 (4.08 g) was introduced as free base in eight
portions (1  120 mg + 3  360 mg + 4  720 mg) using 96%
EtOH (2 mL/min) as the sole eluent and solvent. The chro-
matographic fractions (5 mL) were analyzed by chiral HPLC
under conditions A [(-)-28, tR ) 22.02 min, k′1 ) 1.17; (+)-28,
tR ) 25.00 min, k′2 ) 1.47, R ) 1.25, Res. ) 1.70] and combined
conveniently. In this way, (-)-28 (250 mg, 68% ee) and (+)-28
(360 mg, 69% ee) were obtained. The remaining product
consisted of mixtures of both enantiomers with lower ee’s.
A solution of (-)-28 (250 mg, 68% ee) in MeOH (50 mL) was
treated with active charcoal for 15 min and filtered through
Celite. The filtrate was evaporated at reduced pressure, and
the resulting solid (200 mg) was taken up in MeOH (6 mL)
and treated with excess 0.55 N HCl in Et2O (5 mL). The
organic solvents were removed under reduced pressure, and
the residue (240 mg) was recrystallized from acetonitrile/
MeOH (4:1) (10 mL) to afford (-)-28âHClâ3/4H2O {110 mg,
[R]20D ) -301 (c ) 1.00, MeOH), 95% ee by chiral HPLC on
the liberated base}: mp 242-243 °C; IR 3500-2500 (max at
3464, 3307, 3120, 3029, 2930, 2884, 2834, 2749, 2704, 2681)
(CH, NH, NH+), 1650 and 1588 (ar-C-C and ar-C-N). Anal.
(C17H17FN2âHClâ3/4H2O) C, H, N.
A solution of (+)-28 (360 mg, 69% ee) in MeOH (50 mL) was
treated with active charcoal for 15 min and filtered through
Celite. The filtrate was evaporated at reduced pressure, and
the resulting solid (310 mg) was taken up in an acetonitrile/
MeOH mixture in the ratio of 2:1 (15 mL) and treated with
excess 0.55 N HCl in Et2O (7 mL). The volatile materials were
removed in vacuo, and the residue (340 mg) was recrystallized
from acetonitrile/MeOH (4:1) (15 mL) to afford a brown solid
consisting of (+)-28âHClâH2O (160 mg, 35% ee). Evaporation
of the mother liquors gave a brown solid residue which was
decolorized with active charcoal for 15 min and filtered through
Celite, and the filtrate was concentrated in vacuo to give a
solid (130 mg) which was recrystallized from a mixture of
acetonitrile/MeOH (4:1) (5 mL) to afford, after drying, pure
(+)-28âHClâH2O {40 mg, [R]20D ) +290 (c ) 1.00, MeOH), 99%
ee by chiral HPLC on the liberated base}: mp 236-238 °C;
IR 3500-2500 (max at 3343, 3195, 2934, 2910, 2863, 2827,
2696) (CH, NH, NH+), 1664 and 1592 (ar-C-C and ar-C-N).
Anal. (C17H17FN2âHClâH2O) C, H, N.
rac-12-Amino-1-fluoro-6,7,10,11-tetrahydro-9-methyl-
7,11-methanocycloocta[b]quinoline Hydrochloride (rac-
29âHCl). This compound was prepared according to the
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procedure described above, with a reaction time of 1 h. On
elution with AcOEt/MeOH (90:10), rac-29 (1.18 g, 66% yield)
was isolated. Subsequent treatment with a solution of HCl
(0.55 N solution in Et2O, 3 equiv), evaporation, and recrystal-
lization of the resulting solid from AcOEt/MeOH (1:1) afforded
rac-29âHCl (23% overall yield): mp 268 °C dec; IR 3700-2000
(max at 3408, 3161) (CH, NH, NH+), 1639 and 1595 (ar-C-C
and ar-C-N). Anal. (C17H17FN2âHCl) C, H, N, Cl.
rac-12-Amino-9-ethyl-6,7,10,11-tetrahydro-3-methyl-
7,11-methanocycloocta[b]quinoline Hydrochloride (rac-
30âHCl). This compound was prepared according to the
procedure described above. On elution with hexane/AcOEt (10:
90), rac-30 (0.68 g, 25% yield) was isolated. Subsequent
treatment with a solution of HCl (0.55 N solution in Et2O, 3
equiv), evaporation, and recrystallization of the resulting solid
from acetonitrile/H2O (1:1) afforded rac-30âHClâ3/2H2O (15%
overall yield): mp 208-210 °C; IR 3500-2500 (max at 3341,
3204, 3088, 3053, 2972, 2925, 2780, 2688) (CH, NH, NH+),
1667 and 1591 (ar-C-C and ar-C-N). Anal. (C19H22N2âHClâ
3/2H2O) C, H, N, Cl.
Preparative Resolution of rac-30 by Chiral MPLC:
(+)-(7R,11R)-30 and (-)-(7S,11S)-30. The chromatographic
resolution of rac-30 was carried out by using MPLC equipment
provided with a column (25  2.5 cm) containing microcrys-
talline cellulose triacetate (15-25 ím), pretreated with a 0.1%
solution of Et3N in EtOH, as the chiral stationary phase. The
sample of rac-30 (800 mg) was introduced as free base in five
portions (3  120 mg + 2  220 mg) using 96% EtOH (2 mL/
min) as the sole eluent and solvent. The chromatographic
fractions (5 mL) were analyzed by chiral HPLC under condi-
tions A [(-)-30, tR ) 20.57 min, k′1 ) 0.33; (+)-30, tR ) 23.38
min, k′2 ) 0.51, R ) 1.55, Res. ) 1.68] and combined
conveniently. In this way, (-)-30 (340 mg, 74% ee) and (+)-30
(220 mg, 94% ee) were obtained. The remaining product
consisted of mixtures of both enantiomers with lower ee’s.
A solution of (-)-30 (340 mg, 74% ee) in MeOH (10 mL) was
treated with excess 0.55 N HCl in Et2O (11 mL), and the
organic solvents were removed under reduced pressure. The
residue (350 mg) was recrystallized from acetonitrile/MeOH
(13:2) (15 mL). The resulting white solid (100 mg) was
separated, and the mother liquors were treated with active
charcoal and concentrated in vacuo. The residue was recrystal-
lized from acetonitrile/MeOH (5:1) (6 mL). The crystalline
white solid obtained (30 mg) was combined with the first one
and recrystallized from acetonitrile/MeOH (4:1) (5 mL) to
afford (-)-30âHClâ1/4H2O {90 mg, [R]20D ) -290 (c ) 1.00,
MeOH), 97% ee by chiral HPLC on the liberated base}: mp >
300 °C dec; IR 3500-2500 (max at 3335, 3176, 2966, 2925,
2901, 2829, 2698) (CH, NH, NH+), 1669 and 1591 (ar-C-C and
ar-C-N). Anal. (C19H22N2âHClâ1/4H2O) C, H, N.
Similarly, from (+)-30 (220 mg, 94% ee), (+)-30âHClâ1/4H2O
{120 mg, [R]20D ) +284 (c ) 1.10, MeOH), 96% ee by chiral
HPLC on the liberated base} was obtained: mp > 300 °C dec;
IR 3500-2500 (max at 3332, 3157, 2962, 2923, 2856, 2689)
(CH, NH, NH+), 1666 and 1590 (ar-C-C and ar-C-N). Anal.
(C19H22N2âHClâ1/4H2O) C, H, N.
rac-12-Amino-9-ethyl-6,7,10,11-tetrahydro-1-methyl-
7,11-methanocycloocta[b]quinoline Hydrochloride (rac-
31âHCl). This compound was prepared according to the
procedure described above, but carrying out the reaction in
1,2-dibromoethane for 18 h. On elution with AcOEt/MeOH (80:
20), rac-31 (1.76 g, 65% yield) was isolated. Subsequent
treatment with a solution of HCl (0.55 N solution in Et2O, 3
equiv), evaporation, and recrystallization of the resulting solid
from MeOH/AcOEt/Et2O (1:5:3) afforded rac-31âHClâ1/2H2O
(41% overall yield): mp 282-283 °C; IR 3500-2500 (max at
3310, 3177, 3091, 3034, 2966, 2932, 2899, 2864, 2750) (CH,
NH, NH+), 1650 and 1588 (ar-C-C and ar-C-N). Anal.
(C19H22N2âHClâ1/2H2O) C, H, N, Cl.
N,N′-Bis(2-cyano-3-methylphenyl)-2-methyl-1,3-ada-
mantanediamine (38). This compound was obtained in an
attempted synthesis of rac-31 through the general procedure,
using 1,2-dichloroethane as solvent and a reaction time of 7
h. On elution with hexane/AcOEt (90:10), adamantanediamine
38 (0.22 g, 15% yield) was isolated: mp 204-206 °C after
recrystallization from hexane/AcOEt (9:1); IR 3381 (NH), 2199
(CN); 1H NMR (CDCl3) ä 0.94 (d, J ) 7.0 Hz, 3 H, 2-CH3),
1.65-1.70 [complex signal, 4 H, 6-H and 8(10)-Hexo], 1.83 [dd,
J ) 12.5 Hz, J′ ) 3.0 Hz, 2 H, 4(9)-Hexo], 2.03 [dm, J ) 12.5
Hz, 2 H, 8(10)-Hendo], 2.23-2.30 (complex signal, 5-H and 7-H),
superimposes in part 2.39 [dm, J ) 12.5 Hz, 2 H, 4(9)-Hendo],
2.41 (s, 6 H, 3′-CH3), 2.96 (q, J ) 7.0 Hz, 1 H, 2-H), 4.37 (br.
s, 2 H, NH), 6.54 (d, J ) 7.5 Hz, 2 H, 4′-H), 6.79 (d, J ) 8.5
Hz, 2 H, 6′-H), 7.19 (dd, J ) 8.5 Hz, J′ ) 7.5 Hz, 2 H, 5′-H);
13C NMR (CDCl3) ä 8.7 (CH3, 2-CH3), 21.0 (CH3, 3′-CH3), 29.2
(CH) and 29.6 (CH) (C5 and C7), 35.8 (CH2, C6), 37.3 [CH2,
C8(10)], 41.9 [CH2, C4(9)], 43.5 (CH, C2), 56.5 [C, C1(3)], 98.7
(C, C2′), 111.0 (CH, C6′), 117.3 (C, 2′-CN), 118.0 (CH, C4′),
132.9 (CH, C5′), 143.0 (C, C3′), 148.8 (C, C1′); EI-MS m/z 410
(M¥+, 9), 279 (M+ - C8H7N2, 100), 147 (M+ - 2C8H7N2 - H,
1). Anal. (C27H30N4â1/2H2O) C, H, N.
Biochemical Studies. AChE inhibitory activity was evalu-
ated spectrophotometrically at 25 °C by the method of Ell-
man,30 using AChE from bovine erythrocytes and acetylthio-
choline iodide (0.53 mM) as substrate. The reaction took place
in a final volume of 3 mL of 0.1 M phosphate-buffered solution
(pH 8.0), containing 0.025 unit of AChE and 333 íM 5,5′-
dithiobis(2-nitrobenzoic) acid (DTNB) solution used to produce
the yellow anion of 5-thio-2-nitrobenzoic acid. Inhibition curves
with different derivatives were performed in triplicate by
incubating with at least 12 concentrations of inhibitor for 15
min. One triplicate sample without inhibitor was always
present to yield the 100% of AChE activity. The reaction was
stopped by the addition of 100 íL of 1 mM eserine, and the
color production was measured at 412 nm. BChE inhibitory
activity determinations were carried out similarly, using
human serum BChE and butyrylthiocholine instead of AChE
and acetylthiocholine.
The drug concentration producing 50% of AChE or BChE
activity inhibition (IC50) was calculated. Results are expressed
as mean ( SEM of at least four experiments. DTNB, acetyl-
thiocholine, butyrylthiocholine, and the enzymes were pur-
chased from Sigma, and eserine was from Fluka.
Neuromuscular Studies. Right and left phrenic nerve-
hemidiaphragms removed from male Sprague-Dawley rats
(250-300 g) were used. Details of the experimental procedures
have been previously described.55 Briefly, rats were lightly
anesthetized with ether and decapitated. After quick dissec-
tion, each phrenic-hemidiaphragm preparation was suspended
in organ baths of 75-mL volume with Krebs-Henseleit solution
of the following composition (mM): NaCl 118, KCl 4.7, CaCl2
2.5, KH2PO4 1.2, NaHCO3 25, and glucose 11.1. The prepara-
tion was bubbled with 5% CO2 in oxygen, and the temperature
was maintained at 25 ( 1 °C. Effects of AChE inhibitors on
neuromuscular junction were assessed as the ability of revers-
ing the partial blockade induced by d-tubocurarine in indi-
rectly elicited twitch responses. The twitches were obtained
by stimulating the phrenic nerve with square pulses of 0.5-
ms duration at 0.2 Hz and a supramaximal voltage. Neuro-
muscular blockade was obtained with the addition of d-tubo-
curarine (1-1.5 íM). Drugs were added when a reduction of
twitch response to 70-80% control values was obtained. The
effect of each drug was evaluated after 15 min of exposure.
To avoid the possible carry-over effects, only one concentration
of inhibitor was tested on each preparation. Several drug
concentrations were evaluated for each AChE inhibitor. To
quantify the reversal effect of each drug, the antagonism index
(AI or percent of antagonism)56 was determined for each
concentration and the AI50 (drug concentration that gives a
50% value of AI) was calculated. d-Tubocurarine was pur-
chased from Sigma.
Molecular Modeling: Methods. The docking study was
performed using the crystallographic structures of T. califor-
nica AChE liganded with THA (1)19 and (-)-huperzine A (7).20
The missing residues from the original PDB file57 were built
up, and their positions were refined with the AMBER pro-
gram.58 Since water molecules are essential in mediating the
interaction of THA and (-)-huperzine A with AChE, all the
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crystallographic water molecules were retained. The enzyme
was modeled in its active form with neutral His440 and
deprotonated Glu327, which form the catalytic triad together
with Ser200. All other ionizable residues were considered in
the standard ionization state at neutral pH, with the excep-
tions of Asp392 and Glu443, which were neutral, and His471,
which was protonated, according to previous numerical titra-
tion calculations.59 The resulting structure was used as the
starting coordinate file in the docking study. The geometry of
the inhibitors (THA, huperzine A, and hybrid derivatives) was
fully optimized at the ab initio HF/6-31G(d) level using the
program Gaussian 94.60 According to the basicity for THA,
huperzine A, and hybrid derivatives, the protonated species
were always considered. Restricted electrostatic-potential fit-
ted charges61 were determined at the HF/6-31G(d) level using
the standard procedure.62,63 van der Waals parameters were
taken from the values parametrized for related atom types in
the AMBER force field.58
To examine the binding mode of the inhibitor, the structure
of the inhibitor-AChE complex was energy-minimized with
the AMBER program. To avoid large distortions in the enzyme,
what might lead to artifactual results, the position of the water
molecules was first energy-minimized for 1000 steps. Then,
the enzyme-water system was reminimized for 2000 steps.
Finally, the whole complex was further refined for another
2000 steps. Assuming that enzyme, inhibitors, and the enzyme-
inhibitor complexes are described by their predominant con-
formational and ionization states, and that entropy contribu-
tions are roughly the same for the different binding modes,
the differences in binding free energies were approximated as
a sum of electrostatic and nonelectrostatic contributions (eq
1). The electrostatic component (¢Gele), which includes the
solvent-screened interaction between drug and enzyme plus
the electrostatic contribution due to changes in hydration, was
determined from a finite difference solution of the Poisson-
Boltzmann (PB) equation.64,65 These calculations were carried
out with the commonly used values of 78 and 4 for the
dielectric permittivities of the aqueous and protein environ-
ments. No ionic effects were considered. To minimize the
uncertainty intrinsic to the calculation, a mixed strategy
combining grid rotations and the focusing method was adopted.
Thus, ¢Gele was averaged from the results obtained from seven
independent calculations, where the grid was rotated along
the different axes, and for each grid rotation, after initial
solution of the PB equation, the calculation was repeated with
a finer grid using the boundary conditions from the preceding
calculation (the grid spacing was 1.5 and 1.1 Å). PB calcula-
tions were performed using the Delphi module implemented
in Insight-II.66 The nonelectrostatic component (¢Gn-ele) was
approximated from the addition of a Lennard-Jones interac-
tion energy (¢EL-J) between drug and enzyme and a term
proportional to the change in solvent-accessible surface (¢GSAS)
following the linear relationship between SAS and hydrocarbon-
transfer free energy observed in solubility studies of small
alkanes.67-70 Particularly, the linear dependence reported by
Sitkoff et al.69 and Tannor et al.,70 where a single coefficient
of 5 cal/(K Å2) is assigned to the microscopic surface tension
of all parts of the surface, was used.
Molecular dynamics simulations were performed using the
all-atom AMBER force field for the AChE-(-)-19 complex to
verifiy the stability of the interactions between inhibitor and
enzyme residues in the proposed putative binding mode. The
energy-minimized structure was heated during 30 ps, and then
a 500-ps molecular dynamics (T ) 298 K) was performed for
data collection. Indeed, we explored the effect of replacing
Phe330 by Tyr, which is present in human AChE. This
replacement was performed in the last structure collected from
the molecular dynamics simulation. The resulting structure
was energy-minimized and heated during 30 ps, and the
resulting structure was used as starting point for a 500-ps
molecular dynamics. The last structure was energy-minimized,
and this structure was used in the computational scheme
mentioned above to determine the binding free energy differ-
ence between (-)- and (+)-enantiomers of 19.
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